Navigation Links
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
Date:1/8/2014

hi Sankyo's impressive capabilities, global reach, and open, collaborative culture make them ideal partners," said Jake Reder, Ph.D., President and Chief Executive Officer of Celdara Medical. "The team at Celdara Medical is excited to work hand-in-hand with Daiichi Sankyo on some of the most challenging problems in human health."

About Daiichi Sankyo


The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information about Daiichi Sankyo, please visit www.daiichisankyo.com.   

About Virtici, LLC

Founded in 2011, Virtici is a privately held product-development company headquartered in Seattle, Washington. Virtici's mission is to improve quality of life and save lives, and is primarily developing products to improve the way we diagnose and treat cancer, autoimmunity, and cardiovascular/metabolic diseases. Virtici, working closely with our affiliate Celdara Medical, partners with inventors and their research institutions, bringing the business and finance expertise to accelerate product development. Working with its partners in the pharmaceutical industry, Virtici connects the entire product development lifecycle by improving innovation, enhancing discovery and increasing product development efficiencies. Fo
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
6. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
10. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
11. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... 2014 According to a new ... Battery, Memory Device, Display, & Microprocessor/MCU), by Application (Imaging, ... by Geography - Global Forecast to 2020", published by ... expected to reach $56.50 Billion by 2020, growing at ... Browse 235 market data Tables and 71 Figures ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... News) -- A blood test that measures DNA from ... better assessment of the state of a man,s disease, ... this blood test could reveal when treatment for ... tumor growth, the researchers suggested. "Our study showed ... prostate cancer and often initially very effective started to ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... are Asian Americans at higher risk of developing type ... the disease at lower body weights? One part of ... high-fiber, low-fat Asian diets to current westernized diets, which ... says George King, M.D., Senior Vice President and Chief ... author of the study. , A Joslin randomized clinical ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... study of its kind, scientists from Toronto,s Centre for Addiction and ... a higher risk of developing schizophrenia. This finding was based on ... to a group that did not use drugs, but also to ... published online on Nov. 8, 2011, at AJP in ...
... University of Colorado Denver announced today that it will ... by the Bill & Melinda Gates Foundation that enables ... health and development challenges. Assistant Professor Zhiyong (Jason) ... Applied Science will pursue an innovative global health research ...
... (November 7, 2011) AMRI (NASDAQ: AMRI) announced today ... Eli Lilly and Company, it anticipates hiring more than ... to support Lilly,s drug discovery programs. The chemists will ... they will support the medicinal chemistry department. This ...
... -- ,Neuromuscular warm-ups may reduce knee injuries among female ... neuromuscular warm-up, an athlete begins with easy cardiovascular exercise ... in the sport. The study included 90 ... from public schools in Chicago. Half the coaches were ...
... have been going electronic, and patients, caregivers, and ... digital world of health information. Now three institutions ... populationpeople with disabilitiescan best access this information. ... Inglis Foundation, also based in Philadelphia, are partnering ...
... Hopkins Center for Injury Research and Policy finds fire ... comprehensive and coordinated approach to fire prevention. The study, ... fire service, highlights the diversity of prevention initiatives underway ... a sense of community are keys to success for ...
Cached Medicine News:Health News:CAMH study suggests increased risk of schizophrenia in heavy methamphetamine users 2Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:Delaware Fire Service offers important lessons for fire prevention programs nationwide 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: